Key result
The REVEAL prognostic equation demonstrated reasonably good discrimination for predicting 1-year overall survival in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension.
Why the study?
No previous studies had investigated the predictive performance of the REVEAL prognostic equation and simplified risk score calculator in patients with SLE-PAH.
Do the REVEAL prognostic models accurately predict 1-year overall survival in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension?
Observational (n=306)
Yes
Do the REVEAL prognostic models accurately predict 1-year overall survival in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension?
The REVEAL prognostic models exhibit good discriminatory ability for predicting 1-year overall survival in patients with SLE-PAH, though caution is needed for specific risk factors like renal insufficiency and WHO FC III.
Answers are grounded in this paper and cite their sources.
Supports cautious REVEAL model use for SLE-PAH stratification; leaves open prospective validation before routine adoption.
No previous studies have investigated the predictive performance of the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) prognostic equation and simplified risk score calculator in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH). We aimed to validate these prediction tools in an external cohort of patients with SLE-PAH. In this study, the validation cohort consisted of patients with SLE-PAH registered in a prospective, multicenter, nationwide database between November 2006 and May2016. The follow-up of patients was censored at 1 year. Discrimination, calibration, model fit, and risk stratification of the REVEAL prognostic equation and simplified risk score calculator were validated. As a result, a total of 306 patients with SLE-PAH were included. The 1-year overall survival rate was 91.5%. The C-index of the prognostic equation was 0.736, demonstrating reasonably good discrimination, and it was greater than that for the simplified risk score calculator (0.710). The overall calibration slope was 0.83, and the Brier score was 0.079. The risk of renal insufficiency and World Health Organization Functional Class III (WHO FC III) were underestimated, and the risk assigned to a heart rate >92 bpm in the REVEAL prognostic models was not observed in our validation cohort. Both model discrimination and calibration were poor in the very high-risk group. In conclusion, the REVEAL models exhibit good discriminatory ability when predicting 1-year overall survival in patients with SLE-PAH. Findings from both models should be interpreted with caution in cases of renal insufficiency, WHO FC III, and heart rate >92 bpm.
No takes yet. Share an insight, caveat, or question.
Qu et al. (2021) conducted an observational in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension (SLE-PAH) (n=306). REVEAL prognostic equation and simplified risk score calculator was evaluated on 1-year overall survival discrimination (C-index) (C-index 0.736). The REVEAL prognostic equation demonstrated reasonably good discrimination for predicting 1-year overall survival in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: